Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors

Specific anti-coronaviral drugs complementing available vaccines are urgently needed to fight the COVID-19 pandemic. Given its high conservation across the betacoronavirus genus and dissimilarity to human proteases, the SARS-CoV-2 main protease (M(pro)) is an attractive drug target. SARS-CoV-2 M(pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ullrich, Sven, Sasi, Vishnu M., Mahawaththa, Mithun C., Ekanayake, Kasuni B., Morewood, Richard, George, Josemon, Shuttleworth, Laura, Zhang, Xiaobai, Whitefield, Cassidy, Otting, Gottfried, Jackson, Colin, Nitsche, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378659/
https://www.ncbi.nlm.nih.gov/pubmed/34418570
http://dx.doi.org/10.1016/j.bmcl.2021.128333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378659/
https://www.ncbi.nlm.nih.gov/pubmed/34418570
http://dx.doi.org/10.1016/j.bmcl.2021.128333

Ejemplares similares